Table 2.

Intraocular pressure analysis and adverse events in the study eyes

	Vitrectomised group	Non-vitrectomised group
No of patients with IOP > 20 mmHg (%)	5 (50%)	2 (29%)
No of patients with IOP > 24 mmHg (%)	3 (30%)	1 (14%)
Patients first presentation of IOP > 20 mmHg/treatment round (%)
1st round	3 patients (30%)	1 patient (14%)
2nd round	1 patient (10%)	1 patient (14%)
3rd round	1 patient (10%)	None
Mean IOP per treatment round
Baseline	12.9 mmHg	13.5 mmHg
End of 1st round	14.2 mmHg	14.2 mmHg
End of 2nd round	15.4 mmHg	15.1 mmHg
End of 3rd round (18 months)	15.0 mmHg	15.1 mmHg
Mean IOP increase in 18 months of treatment	+2.1 mmHg	+1.67 mmHg
Other adverse events
Conjunctiva haemorrhage (%)	4 (40%)	3 (42.8%)
Mild ocular pain (%)	2 (20%)	3 (42.8%)
Foreign body sensation (%)	2 (20%)	2 (28.5%)